Monday 23rd April 2018, 3:00pm
Synpromics Ltd, the leader in gene control, announces a partnership with Lonza Pharma & Biotech to further develop its inducible promoter system and improve manufacturing of biopharmaceuticals. The 18-month project has been made possible through the award of a £235,000 grant, part of the medicines manufacturing competition from Innovate UK.
One of the current challenges in the biotech industry is the production of certain biological drugs that can be toxic to host producer cell lines, thereby inhibiting bioproduction.
To overcome this challenge, Synpromics has employed its proprietary
technology to develop new synthetic inducible/repressible cell-systems
that are driven by non-toxic physiological or chemical stimulus, making
them ideal for improving productivity and minimising costs during
bioproduction.
The new systems demonstrate exquisite control of gene expression and offer significant advantages over currently available systems as they are small, can be driven from one plasmid, can incorporate multiple expression cassettes and offer fine-tuning of gene expression.
"Our primary goal in the first 18 months of this programme will be to validate and comprehensively understand the features and benefits of the Synpromics inducible promoter platform in an industrial setting, using well characterised model proteins. Once validated in an industrially relevant situation, the system will be further tested and incorporated into process development for biomanufacturing novel therapeutic constructs."
"Through this important collaboration, we aim to increase overall
flexibility in bioproduction using Synpromics’ inducible promoter
platform, and ultimately provide the broader biopharmaceutical industry
with powerful new tools to increase the number and type of proteins that
can be produced from CHO cells."
"As part of Lonza Pharma & Biotech's strategy to drive next-generation biomanufacturing, we will be supporting Synpromics in testing and validating their inducible promoter in our established GS expression system®."
"This award is a perfect example of how Innovate UK is encouraging companies to come together to bring new ideas to market."
This collaboration is the latest in a series of advantageous partnerships for Synpromics, furthering its growth and development as a company, and distinguishing Synpromics as an industry leader in the cell and gene therapy, and bioprocessing sectors.
Further information:
Corporate Contact:Dr David Venables
CEO Synpromics Ltd
T: +44 (0)7825 323439
E: David.Venables@synpromics.com
Deborah Cockerill / Emma Pickup / Juliette Craggs
Sciad Communications Ltd?
T: +44 (0)20 7470 8801
E: synpromics@sciad.com
Roslin Innovation Centre
The University of Edinburgh
Easter Bush Campus
Midlothian EH25 9RG
